Literature DB >> 20959807

Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme.

Min Ren1, Qing Guo, Liang Guo, Martin Lenz, Feng Qian, Rory R Koenen, Hua Xu, Alexander B Schilling, Christian Weber, Richard D Ye, Aaron R Dinner, Wei-Jen Tang.   

Abstract

Macrophage inflammatory protein-1 (MIP-1), MIP-1α (CCL3) and MIP-1β (CCL4) are chemokines crucial for immune responses towards infection and inflammation. Both MIP-1α and MIP-1β form high-molecular-weight aggregates. Our crystal structures reveal that MIP-1 aggregation is a polymerization process and human MIP-1α and MIP-1β form rod-shaped, double-helical polymers. Biophysical analyses and mathematical modelling show that MIP-1 reversibly forms a polydisperse distribution of rod-shaped polymers in solution. Polymerization buries receptor-binding sites of MIP-1α, thus depolymerization mutations enhance MIP-1α to arrest monocytes onto activated human endothelium. However, same depolymerization mutations render MIP-1α ineffective in mouse peritoneal cell recruitment. Mathematical modelling reveals that, for a long-range chemotaxis of MIP-1, polymerization could protect MIP-1 from proteases that selectively degrade monomeric MIP-1. Insulin-degrading enzyme (IDE) is identified as such a protease and decreased expression of IDE leads to elevated MIP-1 levels in microglial cells. Our structural and proteomic studies offer a molecular basis for selective degradation of MIP-1. The regulated MIP-1 polymerization and selective inactivation of MIP-1 monomers by IDE could aid in controlling the MIP-1 chemotactic gradient for immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959807      PMCID: PMC3020635          DOI: 10.1038/emboj.2010.256

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

1.  Distinct patterns and kinetics of chemokine production regulate dendritic cell function.

Authors:  F Sallusto; B Palermo; D Lenig; M Miettinen; S Matikainen; I Julkunen; R Forster; R Burgstahler; M Lipp; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1999-05       Impact factor: 5.532

2.  Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta.

Authors:  W Koopmann; C Ediriwickrema; M S Krangel
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

3.  Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants.

Authors:  L G Czaplewski; J McKeating; C J Craven; L D Higgins; V Appay; A Brown; T Dudgeon; L A Howard; T Meyers; J Owen; S R Palan; P Tan; G Wilson; N R Woods; C M Heyworth; B I Lord; D Brotherton; R Christison; S Craig; S Cribbes; R M Edwards; S J Evans; R Gilbert; P Morgan; E Randle; N Schofield; P G Varley; J Fisher; J P Waltho; M G Hunter
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

4.  Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans.

Authors:  L Wagner; O O Yang; E A Garcia-Zepeda; Y Ge; S A Kalams; B D Walker; M S Pasternack; A D Luster
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

5.  A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.

Authors:  S H Bernstein; C J Eaves; R Herzig; J Fay; J Lynch; G L Phillips; N Christiansen; D Reece; S Ericson; M Stephan; M Kovalsky; K Hawkins; H Rasmussen; A Devos; G P Herzig
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

6.  Identification of a glycosaminoglycan binding surface on human interleukin-8.

Authors:  G S Kuschert; A J Hoogewerf; A E Proudfoot; C W Chung; R M Cooke; R E Hubbard; T N Wells; P N Sanderson
Journal:  Biochemistry       Date:  1998-08-11       Impact factor: 3.162

7.  BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.

Authors:  M G Hunter; L Bawden; D Brotherton; S Craig; S Cribbes; L G Czaplewski; T M Dexter; A H Drummond; A H Gearing; C M Heyworth; B I Lord; M McCourt; P G Varley; L M Wood; R M Edwards; P J Lewis
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

8.  Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.

Authors:  Qing Guo; Marika Manolopoulou; Yao Bian; Alexander B Schilling; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2009-11-05       Impact factor: 5.469

9.  Requirement of MIP-1 alpha for an inflammatory response to viral infection.

Authors:  D N Cook; M A Beck; T M Coffman; S L Kirby; J F Sheridan; I B Pragnell; O Smithies
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

Review 10.  The growth inhibitory role and potential clinical value of macrophage inflammatory protein 1 alpha in myeloid leukaemias.

Authors:  P J Owen-Lynch; L G Czaplewski; M G Hunter; A D Whetton
Journal:  Leuk Lymphoma       Date:  1998-06
View more
  65 in total

1.  Ubiquitin is a novel substrate for human insulin-degrading enzyme.

Authors:  Luis A Ralat; Vasilios Kalas; Zhongzhou Zheng; Robert D Goldman; Tobin R Sosnick; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2010-12-23       Impact factor: 5.469

Review 2.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Authors:  Wei-Jen Tang
Journal:  Trends Endocrinol Metab       Date:  2015-12-02       Impact factor: 12.015

Review 3.  Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function.

Authors:  C L Salanga; T M Handel
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

4.  Biochemical and biophysical characterization of cytokine-like protein 1 (CYTL1).

Authors:  Aurelie Tomczak; Kavita Singh; Apostolos G Gittis; Joohee Lee; David N Garboczi; Philip M Murphy
Journal:  Cytokine       Date:  2017-05-04       Impact factor: 3.861

Review 5.  Chemokine receptor oligomerization and allostery.

Authors:  Bryan Stephens; Tracy M Handel
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 6.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

7.  Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data.

Authors:  Xu Wang; Caroline Watson; Joshua S Sharp; Tracy M Handel; James H Prestegard
Journal:  Structure       Date:  2011-08-10       Impact factor: 5.006

8.  Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.

Authors:  Julie Charton; Marion Gauriot; Jane Totobenazara; Nathalie Hennuyer; Julie Dumont; Damien Bosc; Xavier Marechal; Jamal Elbakali; Adrien Herledan; Xiaoan Wen; Cyril Ronco; Helene Gras-Masse; Antoine Heninot; Virginie Pottiez; Valerie Landry; Bart Staels; Wenguang G Liang; Florence Leroux; Wei-Jen Tang; Benoit Deprez; Rebecca Deprez-Poulain
Journal:  Eur J Med Chem       Date:  2014-12-04       Impact factor: 6.514

9.  Molecular basis of substrate recognition and degradation by human presequence protease.

Authors:  John V King; Wenguang G Liang; Kathryn P Scherpelz; Alexander B Schilling; Stephen C Meredith; Wei-Jen Tang
Journal:  Structure       Date:  2014-06-12       Impact factor: 5.006

10.  Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.

Authors:  Wenguang G Liang; Catherine G Triandafillou; Teng-Yi Huang; Medel Manuel L Zulueta; Shiladitya Banerjee; Aaron R Dinner; Shang-Cheng Hung; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.